
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 5/1/24**
(See policy history boxes for previous effective dates)

Title: Genetic Testing- Molecular Testing for the Diagnosis and Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreaticobiliary Lesions (e.g., PathFinderTG[®], PancaGEN, BarreGEN)

Description/Background

MUCINOUS NEOPLASMS OF THE PANCREAS

True pancreatic cysts are fluid-filled, cell-lined structures, which are most commonly mucinous cysts (intraductal papillary mucinous neoplasm [IPMN] and mucinous cystic neoplasm [MCN]), which are associated with future development of pancreatic cancers. Although mucinous neoplasms associated with cysts may cause symptoms (e.g., pain, pancreatitis), an important reason that such cysts are followed is the risk of malignancy, which is estimated to range from 0.01% at the time of diagnosis to 15% in resected lesions.

Management

Given the rare occurrence but poor prognosis of pancreatic cancer, there is a need to balance potential early detection of malignancies while avoiding unnecessary surgical resection of cysts. Several guidelines address the management of pancreatic cysts, but high-quality evidence to support these guidelines is not generally available. Although recommendations vary, first-line evaluation usually includes examination of cyst cytopathologic or radiographic findings and cyst fluid carcinoembryonic antigen (CEA). In 2012, an international consensus panel published statements for the management of IPMN and MCN of the pancreas.¹ These statements are referred to as the Fukouka Consensus Guidelines and were based on a symposium held in Japan in 2010 and updated a 2006 publication (Sendai Consensus Guidelines) by this same group.² The panel recommended surgical resection for all surgically fit patients with main duct IPMN or MCN. For branch duct IPMN, surgically fit patients with cytology suspicious or positive for malignancy are recommended for surgical resection, but patients without “high-risk stigmata” or “worrisome features” may be observed with surveillance. “High-risk stigmata” are: obstructive jaundice in proximal lesions (head of the pancreas); presence of an enhancing solid component within the cyst; or 10 mm or greater dilation of the main pancreatic duct. “Worrisome features”

are: pancreatitis; lymphadenopathy; cyst size 3 cm or greater; thickened or enhancing cyst walls on imaging; 5 to 10 mm dilation of the main pancreatic duct; or abrupt change in pancreatic duct caliber with distal atrophy of the pancreas.

In 2015, the American Gastroenterological Association published a guideline on the evaluation and management of pancreatic cysts; it recommends patients undergo further evaluation with endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) only if the cyst has 2 or more worrisome features (size ≥ 3 cm, a solid component, a dilated main pancreatic duct).³ The guideline recommends that patients with a solid component, dilated pancreatic duct and/or “concerning features” on EUS-FNA should undergo surgery.

BARRETT ESOPHAGUS

Barrett esophagus refers to the replacement of normal esophageal epithelial layer with metaplastic columnar cells in response to chronic acid exposure from gastroesophageal reflux disease (GERD). The metaplastic columnar epithelium is a precursor to esophageal adenocarcinoma (EAC). These tumors frequently spread before symptoms are present so detection at an early stage might be beneficial.

Management

Surveillance for EAC is recommended for those diagnosed with Barrett esophagus.⁴ However, there are few data to guide recommendations about management and surveillance, and many issues are controversial. In 2015 guidelines from the American College of Gastroenterology (ACG) and a consensus statement from an international group of experts (Benign Barrett’s and Cancer Taskforce [BOB CAT]) regarding management of Barrett esophagus were published.⁴ ACG recommendations for surveillance are stratified by presence of dysplasia. When no dysplasia is detected, ACG reports the estimated risk of progression to cancer for patients ranges from 0.2% to 0.5% per year and ACG recommends endoscopic surveillance every 3 to 5 years. For low-grade dysplasia, the estimated risk of progression is about 0.7% per year and ACG recommends endoscopic therapy or surveillance every 12 months. For high-grade dysplasia, the estimated risk of progression is about 7% per year and ACG recommends endoscopic therapy.⁵ The BOB CAT consensus group did not endorse routine surveillance for people with no dysplasia and was unable to agree on surveillance intervals for low-grade dysplasia.⁴

SOLID PANCREATICOBILIARY LESIONS

Solid pancreaticobiliary lesions refer to lesions found on the pancreas, gallbladder, or biliary ducts. A solid lesion may be detected as an incidental finding on computed tomography scans performed for another reason, though this occurs rarely. The differential diagnosis of a solid pancreatic mass includes primary exocrine pancreatic cancer, pancreatic neuroendocrine tumor, lymphoma, metastatic cancer, chronic pancreatitis, or autoimmune pancreatitis.

Management

Currently, if a transabdominal ultrasound confirms the presence of a lesion, an abdominal computed tomography scan is performed to confirm the presence of the mass and determine disease extent. If the computed tomography provides enough information to recommend a resection and if the patient is able to undergo the procedure, no further testing is necessary. If the diagnosis remains unclear, additional procedures may be recommended. Symptomatic patients undergo cytology testing. If results from cytology testing are inconclusive, fluorescent in situ hybridization molecular testing of solid pancreaticobiliary lesions is recommended.

PancraGEN topographic genotyping is being investigated as either an alternative to or as an adjunct to fluorescent in situ hybridization in the diagnostic confirmation process.

TOPOGRAPHIC GENOTYPING

Topographic genotyping (TG), also called molecular anatomic pathology, integrates microscopic analysis (anatomic pathology) with molecular tissue analysis. Under microscopic examination of tissue and other specimens, areas of interest may be identified and microdissected to increase tumor cell yield for subsequent molecular analysis. TG may permit pathologic diagnosis when first-line analyses are inconclusive.⁶

RedPath Integrated Pathology (now Interpace Diagnostics) has patented a proprietary platform, called PathFinderTG®, to provide mutational analyses of patient specimens. The patented technology permits analysis of tissue specimens of any size, “including minute needle biopsy specimens,” and any age, “including those stored in paraffin for over 30 years.”⁷ RedPath currently offers 5 PathFinderTG® tests (listed and briefly described in Table 1). Interpace currently describes, in detail, one PathFinderTG test called PancraGEN on its website and describes another PathFinder test called BarreGEN™ as “in the pipeline” (listed and briefly described in Table 1).⁸ As stated on the company website, PancraGEN integrates molecular analyses with first-line results (when these are inconclusive) and pathologist interpretation.⁹ The manufacturer calls this technique integrated molecular pathology. Test performance information is not provided on the website.

Table 1. PathFinderTG Tests⁸

Test	Description	Specimen Types
PathFinderTG Pancreas (now called PancraGen)	Uses loss of heterozygosity markers, oncogene variants, and DNA content abnormalities to stratify patients according to their risk of progression to cancer	Pancreatobiliary fluid/ERCP brush, pancreatic masses, or pancreatic tissue
PathFinderTG Barrett (now called BarreGen)	Measures the presence and extent of genomic instability and integrates those results with histology	Esophageal tissue

ERCP: endoscopic retrograde cholangiopancreatography

Regulatory Status:

These patented diagnostic tests are available only through RedPath Integrated Pathology (Pittsburgh, PA). The PathFinderTG® Molecular Test is not subject to review by the U.S. Food and Drug Administration (FDA) because it is a laboratory-developed test (LDT) conducted only at RedPath Integrated Pathology’s licensed laboratory. Laboratories performing LDTs must be licensed for high complexity testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). RedPath is licensed under CLIA.

Medical Policy Statement

Molecular testing using the PathFinder TG[®] System (e.g., PancraGEN and BarreGEN) is experimental/investigational for all indications including the evaluation of pancreatic cyst fluid, Barrett esophagus, and solid pancreaticobiliary lesions. The impact of this technology on health outcomes compared with existing alternatives (i.e., incremental value) is not known.

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

84999

89240

0313U

Rationale

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

When this evidence review was created, it evaluated 3 representative applications of topographic genotyping—pancreatic cysts, gliomas, and Barrett esophagus. At present, Interpace Diagnostics offers tests using its technology to evaluate patients with pancreatic cysts, Barrett esophagus, and solid pancreaticobiliary lesions, which are the focus of the current review.

PANCREATIC CYSTS

Clinical Context and Test Purpose

The widespread use and increasing sensitivity of computed tomography (CT) and magnetic resonance imaging scans have been associated with marked increase in the finding of incidental pancreatic cysts.¹⁰⁻¹² In individuals without history of symptoms of pancreatic disease undergoing CT and magnetic resonance imaging, studies have estimated the prevalence of pancreatic cysts as being between 2% and 3%.¹¹⁻¹² Although data have suggested that the malignant transformation of these cysts is very rare,¹³ due to the potential life-threatening prognosis of pancreatic cancer, an incidental finding can start an aggressive clinical workup.

Many cysts can be followed with imaging surveillance. Recommendations for which cysts should proceed for surgical resection vary. If imaging of the cyst is inconclusive, additional testing of cystic pancreatic lesions is usually performed by endoscopic ultrasound with fine-needle aspiration (EUS-FNA) sampling of the fluid and cyst wall for cytologic examination and analysis. Cytologic examination of these lesions can be difficult or indeterminate due to low cellularity, cellular degeneration, or procedural difficulties. Ancillary tests (e.g., amylase, lipase, carcinoembryonic antigen levels) often are performed on cyst fluid to aid in diagnosis and prognosis but results still may be equivocal.

International consensus has recommended surgical resection for all surgically fit individuals with mucinous cystic neoplasm or main duct intraductal papillary mucinous neoplasm.¹ This is due to the uncertainty of the natural history of mucinous cystic neoplasm and main duct intraductal papillary mucinous neoplasm and the presumed malignant potential of all types.^{2,14,15} Estimates of morbidity and mortality following resection vary. The 2015 American Gastroenterological Association technical review combined estimates into a pooled mortality rate of about 2% and serious complication rate of about 30%.¹⁶ Therefore, there is a need for more accurate prognosis to optimize detection of malignancy while minimizing unnecessary surgery and treatment.

The question addressed in this evidence review is: Does testing using PancreaGEN topographic genotyping in addition to standard diagnostic or prognostic practices improve the net health outcome in individuals with pancreatic cysts?

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest is individuals for whom there remains clinical uncertainty regarding the malignant potential of a pancreatic cyst after comprehensive first-line evaluation and who are being considered for surgery.

Interventions

The relevant intervention of interest is PancreaGEN topographic genotyping in addition to standard diagnostic or prognostic practices.

PathFinderTG® (Interpace Diagnostics) mutational profiles in an attempt to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. The manufacturer's website states specifically that the PancreaGEN technology is "intended to be an adjunct to first

line testing” and suggests that the test is useful in assessing who will benefit most from surveillance and or surgery.¹⁷ The clinical purpose of PancreGEN is to allow patients with low-risk cysts to avoid unnecessary surgery or to select patients with malignant lesions for surgery more accurately. PancreGEN would likely be used in conjunction with clinical and radiologic characteristics, along with cyst fluid analysis; therefore, one would expect an incremental benefit to using the test.

As shown in Table 1, the PathFinderTG Pancreas test (now called PancreGEN) combines measures of loss of heterozygosity (LOH) markers, oncogene variants, and DNA content abnormalities to stratify patients according to their risk of progression to cancer. According to Al-Haddad et al (2015), who reported results from a registry established with support from the manufacturer,¹⁸ the current diagnostic algorithm is as follows in Table 2.

Table 2. Diagnostic Algorithm for PancreGEN

Diagnostic Category	Molecular Criteria^a	Coexisting Concerning Clinical Features^b
Benign	DNA lacks molecular criteria	Not considered for this diagnosis
Statistically indolent	DNA meets 1 molecular criterion	None
Statistically higher risk	DNA meets 1 molecular criterion	1 or more
Aggressive	DNA meets at least 2 molecular criteria	Not considered for this diagnosis

Al-Haddad et al (2015).¹⁹

^a Molecular criteria: (1) a single high-clonality variant, (2) elevated level of high-quality DNA, (3) multiple low-clonality variants; (4) a single low-clonality oncogene variant.

^b Includes any of the following: cyst size >3 cm, growth rate >3 mm/y, duct dilation >1 cm, carcinoembryonic antigen level >1000 ng/mL, cytologic evidence of high-grade dysplasia.

Comparators

The relevant comparators of interest are standard diagnostic and prognostic techniques, including imaging using magnetic resonance imaging with magnetic resonance cholangiopancreatography, multidetector CT, or intraductal ultrasound, EUS-FNA, cytology, and amylase and carcinoembryonic antigen in cyst fluid. In the absence of definitive malignancy by first-line testing, indications for surgery are frequently based on morphologic features according to 2012 international consensus panel statements for the management of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm.¹

Outcomes

The primary outcomes of interest are survival and complications of surgery. Beneficial outcomes resulting from a true test result are the initiation of appropriate treatment or avoiding unnecessary surgery. Harmful outcomes resulting from a false-test result are unnecessary surgery and failing to receive timely appropriate surgery or treatment. The American Gastroenterological Association has recommended surveillance of cysts that do not meet criteria for resection for 5 years.³

Study Selection Criteria

For the evaluation of the clinical validity of the PancreGEN test (including the algorithm), studies that met the following eligibility criteria were considered:

- Reported on the accuracy of the patented PathFinder Pancreas or PancreGEN technology for classifying patients into prognostic categories for malignancy;

- Included a suitable reference standard (long-term follow-up for malignancy; histopathology from surgically resected lesions);
- Patient and sample clinical characteristics were described; and
- Patient and sample selection criteria were described.

Several studies were excluded from the evaluation of the clinical validity of the PancreaGEN test for the following reasons: they assessed components of the test separately for the malignancy outcome,¹⁹⁻³² did not include information needed to calculate performance characteristics for the malignancy outcome,³³ did not describe how the reference standard diagnoses were established,³⁴ did not use a suitable reference standard,^{35,36} did not adequately describe the patient characteristics,^{21,31,37} or did not adequately describe patient selection criteria.^{20,21,31,33,37} The following paragraphs describe the selected studies, which included 1 systematic review and 3 retrospective studies.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Review of Evidence

Retrospective Studies

Three retrospective studies provide evidence on the clinical validity of topographic genotyping with Pathfinder TG (PancreaGEN) tests (Table 3). The largest of these, conducted by Al-Haddad et al (2015)¹⁹, was an analysis of 492 patients enrolled in the National Pancreatic Cyst Registry (NPCR). Although study investigators reviewed the records of 1862 NPCR patients, the majority of these (n=1,372) did not meet study inclusion criteria, primarily due to inadequate duration of follow-up. Investigators assessed the ability of the PathFinderTG and of the 2012 Sendai International Consensus Guideline classification to predict malignancy risk in patients with pancreatic cysts. At median follow-up of 35 months, for patients with benign and statistically indolent diagnoses (range, 23-92 months), 66 (35%) patients were diagnosed with a malignancy. Measures of diagnostic accuracy appear in Table 3. The authors noted that the PathFinderTG diagnostic criteria have evolved and older cases in the registry were recategorized using the new criteria. Of the 492 registry cases included, 468 (95%) had to be recategorized using the current diagnostic categories. A strength of the study was its inclusion of both surgery and surveillance groups. Limitations included the retrospective design, exclusion of 74% of all registry patients due primarily to insufficient follow-up; relatively short follow-up for observing the malignant transformation of benign lesions; and the exclusion of patients classified as malignant by international consensus criteria who would not have undergone PathFinderTG testing. The reclassification of the majority of the PathFinderTG diagnoses due to evolving criteria between 2011 and 2014 also make it questionable whether the older estimates of performance characteristics are relevant. Two other, single-center studies conducted by Winner et al (2015)³⁹ and Malhotra et al (2014)⁴⁰, retrospectively analyzed data from patients who were evaluated for pancreatic cysts between 2006 and 2012 and who had surgical resection and molecular analysis with PathFinderTG. Results of these studies are summarized in Table 3.

Table 3. Retrospective Studies of Clinical Validity of PancreGEN

Study	Population	N	Reference Standard	Performance Characteristics (95% CI), %	
				PancreGEN	International Consensus Guideline
Al-Haddad et al (2015) ¹⁹	<ul style="list-style-type: none"> 69% female; race/ethnicity not reported Patients who had undergone IMP testing prescribed by their physician and for whom clinical outcomes were available with 23-mo FU 	492	Long-term FU, surgical pathology	<ul style="list-style-type: none"> Sens: 83 (72 to 91) Spec: 91 (87 to 93) PPV: 58 (47 to 68) NPV: 97 (95 to 99) 	<ul style="list-style-type: none"> Sens: 91 (81 to 97) Spec: 46 (41 to 51) PPV: 21 (16 to 26) NPV: 97 (94 to 99)
Winner et al (2015) ³⁹	<ul style="list-style-type: none"> 60% female; 85% White (other race/ethnicity not reported) Patients evaluated for pancreatic cysts, had surgical resection, cyst fluid, and molecular analysis <p>36 patients evaluated for pancreatic cysts, had surgical resection, cyst fluid, and molecular analysis</p>	36	Surgical pathology	<ul style="list-style-type: none"> Sens: 67 (31 to 91) Spec: 81 (61 to 93) PPV: 55 (25 to 82) NPV: 88 (68 to 97) 	NA
Al-Haddad et al (2015)[Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integ.... ; 47(2): 136-42. PMID 25314329]	492 patients who had undergone IMP testing prescribed by their physician and for whom clinical outcomes were available with 23-mo FU		Long-term FU, surgical pathology	<ul style="list-style-type: none"> Sens: 83 (72 to 91) Spec: 91 (87 to 93) PPV: 58 (47 to 68) NPV: 97 (95 to 99) 	<ul style="list-style-type: none"> Sens: 91 (81 to 97) Spec: 46 (41 to 51) PPV: 21 (16 to 26) NPV: 97 (94 to 99)
Malhotra et al (2014) ⁴⁰	<ul style="list-style-type: none"> Demographic characteristics not reported Patients with pancreaticobiliary masses with cytologic diagnosis of atypical, negative, or 	26	Surgical pathology or oncology FU report	<ul style="list-style-type: none"> Sens: 47 (24 to 71) Spec: 100 (63 to 100) PPV: 100 (60 to 100) 	NA

	<p style="text-align: center;">indeterminate and minimum 3-mo FU</p> <p>26 patients with pancreaticobiliary masses with cytologic diagnosis of atypical, negative, or indeterminate and minimum 3- mo FU</p>			<ul style="list-style-type: none"> NPV: 50 (27 to 73) 	
--	--	--	--	--	--

CI: confidence interval; FU: follow-up; IMP: integrated molecular pathology; N/A: not applicable; NPV: negative predictive value; PPV: positive predictive value.

Tables 4 and 5 display notable gaps identified in each study.

Table 4. Relevance Study Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Winner et al (2015) ³⁹	4. Patients in study were all scheduled for surgery, while not all patients with pancreatic cysts typically get surgical referrals		2. Comparisons to a reference standard were not made		
Al-Haddad et al (2015) ¹⁹		2. As the criteria for the test have evolved, older cases in the registry had to be recategorized based on new criteria			
Malhotra et al (2014) ⁴⁰			2. Comparisons to a reference standard were not made	3. Key clinical validity outcomes not reported and calculated by BCBSA	1. Follow-up of 3 mo

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

^c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

^d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

^e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

Table 5. Study Design and Conduct Limitations

Study	Selection ^a	Blinding ^b	Delivery of Test ^c	Selective Reporting ^d	Data Completeness ^e	Statistical ^f
Winner et al (2015) ³⁹ .		1. No discussion whether cytologists blinded to other test results				
Al-Haddad et al (2015) ¹⁹ .					1. High number of samples from registry excluded due to insufficient follow-up (74%)	
Malhotra et al (2014) ⁴⁰ .		1. No discussion whether cytologists blinded to other test results				1. Small sample size did not allow for significance tests

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

^a Selection key: 1. Selection not described; 2. Selection not random or consecutive (i.e., convenience).

^b Blinding key: 1. Not blinded to results of reference or other comparator tests.

^c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

^d Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data. ^f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

Direct demonstration of clinical utility would require evidence that PancreGEN produces incremental improvement in survival (by detecting malignant and potentially malignant cysts) or decreased morbidity of surgery (by avoiding surgery for cysts highly likely benign) when used adjunctively with the current diagnostic and prognostic standards.

No studies assessing clinical utility were identified.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The 2015 publication by Al-Haddad et al from the National Pancreatic Cyst Registry also assessed evidence of clinical utility by describing how the PancreGEN might provide incremental benefit over consensus guidelines.¹⁹ In 289 patients who met consensus criteria for surgery, 229 had a benign outcome. The PancreGEN algorithm correctly classified 193 (84%) of the 229 as benign or statistically indolent. The consensus guidelines classified 203

patients as appropriate for surveillance and 6 of them had a malignant outcome. The PancreGEN correctly categorized 4 of 6 as high risk (see Table 6). The complete cross-classification of the 2 classification strategies by outcomes was not provided.

Using the same subset of 491 patients described in the previous section from the National Pancreatic Cyst Registry, Loren et al published results in 2016 comparing the association between PancreGEN diagnoses and Sendai and Fukouka consensus guideline recommendations with clinical decisions regarding intervention and surveillance.⁴¹ Patients were categorized as (1) “low-risk” or “high-risk” using the Interspace algorithm for PancreGEN diagnoses; (2) meeting “surveillance” criteria or “surgery” criteria using consensus guidelines; and (3) having “benign” or “malignant” outcomes during clinical follow-up as described previously. In addition, the real-world management decision was categorized as “intervention” if there was a surgical report, surgical pathology, chemotherapy or positive cytology within 12 months of the index EUS-FNA, and as “surveillance” otherwise. Among patients who actually received surveillance as the real-world decision, 57% were also classified as needing surveillance according to consensus guidelines and 96% were classified as low risk according to PancreGEN (calculated from data in Table 3). However, among patients who had an intervention as the real-world decision, 81% were classified as candidates for surgery by consensus guidelines and 40% were classified as high risk by PancreGEN. In univariate logistic regression analyses, the odds ratio (OR) for the association between PancreGEN diagnoses and real-world decision was higher (OR=16.8; 95% CI, 9.0 to 34.4) than the OR for the association between the consensus guidelines recommendations versus real-world decision (OR=5.6; 95% CI, 3.7 to 8.5). In 8 patients, the PancreGEN diagnosis was high risk and the consensus guideline classification was low risk. In 7 of these cases, the patient actually received an intervention resulting in the discovery of an additional 4 malignancies that would have been missed using the consensus guideline classification alone and in the remaining 1 case the patient underwent surveillance and did not develop a malignancy. In 202 patients, the PancreGEN diagnosis was low risk and the consensus guideline classification was high risk. In 90 of these 202, patients actually had an intervention and 8 additional malignancies were detected. In 112 of these 202, patients received surveillance and 1 additional malignancy occurred in the surveillance group. The cross-tabulation of PancreGEN and international consensus classification by outcome was not shown in Loren et al (2016) but was derived by BCBSA from tables and text and is displayed in Table 6. This study demonstrated that results from PancreGEN testing are associated with real-world decisions, although other factors (e.g., physician judgment, patient preferences) could have affected these decisions.

Table 6. PancreGEN and International Consensus Classifications by Outcome (N=491)

Malignant Outcome			Benign Outcome		
Consensus Classification	PancreGEN Classification		Consensus Classification	PancreGEN Classification	
	Low Risk	High Risk		Low Risk	High Risk
Surveillance	2	4	Surveillance	193	4
Surgery	9	50	Surgery	193	36

Kowalski et al (2016) reported on an analysis of false-negatives from the same 492 records from the NPCR.⁴² Of the 6 cysts found false-negative using consensus classification, 5 cysts

were 2 cm or less (the remaining case did not have data on cyst size) and one reported symptoms (obstructive jaundice). Of the 11 cases that were false-negative according to PancaGEN, 10 were reported to have EUS-FNA sampling limitations, one had a family history of pancreatic cancer, 4 reported symptoms (including pancreatitis, steatorrhea, nausea, bloating, and/or upper abdominal discomfort), and cysts sizes ranged from 0.7 to 6 cm for the 6 for which size was reported.

The best strategy for combining the results of PancaGEN with current diagnostic guidelines is not clear. There is some suggestion that PancaGEN might appropriately classify some cases misclassified by current consensus guidelines, but the sample sizes in the cases where the PancaGEN and consensus guidelines disagree are small, limiting confidence in these results.

Section Summary: Pancreatic Cysts

The evidence for the clinical validity of PancaGEN consists of several retrospective studies. Most evaluated performance characteristics of PancaGEN for classifying pancreatic cysts according to the risk of malignancy without comparison to current diagnostic algorithms. The best evidence of incremental clinical validity comes from the report from the National Pancreatic Cyst Registry which compared PancaGEN performance characteristics to current international consensus guidelines and found that PancaGEN has slightly lower sensitivity (83% vs. 91%), similar NPV (97% vs. 97%) but better specificity (91% vs. 46%) and PPV (58% vs. 21%) compared to the consensus guidelines. The registry study included a very select group of patients, only a small fraction of the enrolled patients, and used a retrospective design. Longer follow-up including more of the registry patients is needed. The manufacturer has indicated that the technology is meant as an adjunct to first-line testing but no algorithm for combining PancaGEN with consensus guidelines for decision making has been proposed, and the data reporting outcomes in patients where the PancaGEN and consensus guideline diagnoses disagreed is limited. There are no prospective studies with a concurrent control demonstrating that PancaGEN can affect patient-relevant outcomes (e.g., survival, time to tumor recurrence, reduction in unnecessary surgeries). The evidence reviewed does not demonstrate that PathFinder^{TG} has incremental clinical value for diagnosis or prognosis of pancreatic cysts and associated cancer.

BARRETT ESOPHAGUS

Clinical Context and Test Purpose

The American Gastroenterological Association (AGA) defines Barrett esophagus as replacement of normal epithelium at the distal esophagus by intestinal metaplasia, which predisposes to malignancy.⁴⁵ Although grading of dysplasia in mucosal biopsies is the current standard for assessing risk of malignant transformation, esophageal inflammation may mimic or mask dysplasia and interobserver variability may yield inconsistent risk classifications.⁴⁶ Additional prognostic information therefore may be potentially useful.

The Interpace website describes BarreGEN as a molecular diagnostic test to “determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus.”³

The question addressed in this evidence review is: Does testing using BarreGEN topographic genotyping in addition to standard prognostic practices improve the net health outcome in individuals with Barrett esophagus?

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest is individuals with Barrett esophagus. It is unclear what other clinical characteristics would identify candidates for BarreGEN or what the previous testing is appropriate before BarreGEN.

Interventions

The relevant intervention of interest is BarreGEN topographic genotyping in addition to standard prognostic practices.

The Interpace website describes BarreGEN as a molecular diagnostic test to “determine the risk of progressing to esophageal cancer in patients with Barrett’s Esophagus.”⁸

Comparators

The relevant comparators of interest are standard prognostic techniques generally include grading of dysplasia from endoscopy with biopsy.

Outcomes

Outcomes of interest are survival and conversion to esophageal cancer. It is not clear how the test would fit into the diagnostic pathway and effect treatment or surveillance recommendations therefore complete specification of other important outcomes is not possible. Because it is not yet clear how this test would be used in practice, follow-up time for outcomes is unclear.

Study Selection Criteria

For the evaluation of the clinical validity of the BarreGEN test (including the algorithm), studies that met the following eligibility criteria were considered:

- Reported on the accuracy of the patented PathFinder Barrett Esophagus or BarreGEN technology for classifying patients into prognostic categories for malignancy;
- Included a suitable reference standard (long-term follow-up for malignancy; histopathology from surgically resected lesions);
- Patient and sample clinical characteristics were described; and
- Patient and sample selection criteria were described.

Two studies were excluded from the evaluation of the clinical validity of the BarreGEN test because it was not clear whether the authors used the marketed version of the BarreGEN test.^{47,48}

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

No relevant studies have been identified assessing the clinical validity of the BarreGEN test.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive

correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

No studies assessing the clinical utility of BarreGEN in this population were found.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

Because evidence for the clinical validity of BarreGEN is lacking, a chain of evidence that would support clinical utility cannot be constructed.

Section Summary: Barrett Esophagus

There is limited evidence evaluating the clinical validity of the BarreGEN test for assessing Barrett esophagus thus, there is no evidence that BarreGEN testing for prognosis of Barrett esophagus adds incremental value to current prognostic assessments.

SOLID PANCREATICOBILIARY LESIONS

Clinical Context and Test Purpose

Pancreatic cancer is usually diagnosed in advanced stages when effective treatment options are limited. Currently, symptomatic patients with solid pancreaticobiliary lesions undergo cytology testing. If results from cytology testing are inconclusive, fluorescent in situ hybridization (FISH) molecular testing of solid pancreaticobiliary lesions is recommended. PancraGEN topographic genotyping is being investigated as either an alternative to or an adjunct to FISH in the diagnosis confirmation process.

The purpose of PancraGEN topographic genotyping in individuals who are symptomatic with high suspicion of cholangiocarcinoma or pancreatic cancer with inconclusive cytology testing results is to potentially confirm a diagnosis, which would inform patient management decisions.

The question addressed in this evidence review is: Does testing using PancraGEN topographic genotyping in addition to standard diagnostic practices improve the net health outcome in individuals with solid pancreaticobiliary lesions?

The following **PICOs** were used to select literature to inform this review.

Populations

The relevant population of interest is symptomatic individuals with high suspicion of cholangiocarcinoma or pancreatic cancer based on endoscopic imaging showing bile duct obstruction or solid mass who receive inconclusive cytology testing results.

Interventions

The test being considered is PancaGEN topographic genotyping, as either an alternative test or adjunct test to FISH molecular testing of solid pancreaticobiliary lesions. FISH is currently considered second-line to standard routine cytology testing.

Comparators

The following tests are currently being used to diagnose cholangiocarcinoma or pancreatic cancer: cytology testing with and without standard molecular FISH testing.

Outcomes

The primary outcome of interest is overall survival. Beneficial outcomes resulting from a true test result are the initiation of appropriate treatment or avoidance of unnecessary surgery. Harmful outcomes resulting from a false test result are unnecessary surgery or failing to receive timely appropriate surgery or chemotherapy.

Study Selection Criteria

For the evaluation of the clinical validity of the PancaGEN test (including the algorithm), studies that met the following eligibility criteria were considered:

- Reported on the accuracy of the patented PathFinder Pancreas or PancaGEN technology for classifying patients into prognostic categories for malignancy;
- Included a suitable reference standard (long-term follow-up for malignancy; histopathology from surgically resected lesions);
- Patient and sample clinical characteristics were described; and
- Patient and sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Prospective and Retrospective Studies

Three studies assessed the clinical validity of PancaGEN patients with biliary structures or solid pancreaticobiliary lesions (Table 7).^{47,48,49} The populations of two of the studies were patients being evaluated for biliary strictures. Biliary strictures may be caused by solid pancreaticobiliary lesions, but there are other potential causes such as trauma to the abdomen, pancreatitis, or bile duct stones. The authors did not specify what proportion of the population of patients with biliary strictures had solid pancreaticobiliary lesions. While sensitivity and specificity calculations showed incremental improvements when molecular testing with PancaGEN was added to cytology results, not knowing what proportion of patients with biliary strictures had solid pancreaticobiliary lesions does not permit conclusions specific to patients with solid pancreaticobiliary lesions.

Table 7. Characteristics of Clinical Validity Studies Assessing PancaGEN

Study	Design	Population	N	Diagnostic Test	Comparator	Follow-Up, mo
Khosravi et al (2018) ⁴⁷	Retrospective consecutive sample	<ul style="list-style-type: none">• 56% female; race/ethnicity not reported	232	Cytology plus MP (PancaGEN)	Cytology alone	12

		<ul style="list-style-type: none"> Patients who had EUS-FNA and/or ERCP for solid pancreatic lesions indeterminate by cytology 				
Kushnir et al (2018) ⁴⁸	Prospective consecutive sample	<ul style="list-style-type: none"> 32% female; 89% White, 10% Black, 1% Asian Patients who underwent ERCP for evaluation of biliary strictures 	100	Cytology plus MP (PancraGEN)	Cytology alone; cytology plus FISH; cytology plus FISH and MP	12
Gonda et al (2017) ⁴⁹	Prospective consecutive sample	<ul style="list-style-type: none"> 43% female; race/ethnicity not reported Patients who underwent ERCP for evaluation of biliary strictures, with 2 brushings (1 for cytology, 1 for FISH) 	100	Cytology plus MP (PathFinderTG-Biliary)	Cytology alone; cytology plus FISH; cytology plus FISH and MP	12

ERCP: endoscopic retrograde cholangiopancreatography; EUS-FNA: endoscopic ultrasound fine needle aspiration; FISH: fluorescence in situ hybridization; MP: mutation profiling.

Table 8. Diagnostic Accuracy Results of Clinical Validity Studies Assessing PancraGEN

Study	Diagnostic Test	Sensitivity% (95% CI)	Specificity% (95% CI)	PPV% (95% CI)	NPV% (95% CI)
Khosravi et al (2018) ⁴⁷	Cytology alone	41 (27 to 56)	97 (94 to 99)	80 (59 to 93)	86 (81 to 90)
	MP alone	46 (27 to 67)	94 (87 to 98)	71 (48 to 86)	85 (77 to 92)
	Cytology plus MP	67 (53 to 80)	95 (90 to 97)	81 (65 to 91)	92 (81 to 95)
Kushnir et al (2018) ⁴⁸	Cytology alone	26 (NR)	100 (NR)	NR	NR
	Cytology plus FISH	44 (NR); p<.001	100 (NR)	NR	NR
	Cytology plus MP	56 (NR); p<.001	97 (NR)	NR	NR
	Cytology plus FISH plus MP	66 (NR); p<.001 ^a	97 (NR)	NR	NR
Gonda et al (2017) ⁴⁹	Cytology alone	32 (18 to 48)	100 (91 to 100)	NR	NR

	Cytology plus FISH	51 (35 to 67)	100 (91 to 100)	NR	NR
	Cytology plus MP	51 (35 to 67)	100 (91 to 100)	NR	NR
	Cytology plus FISH plus MP	73 (59 to 86)	100 (91 to 100)	NR	NR

^a p-value compared to cytology alone

CI: confidence interval; FISH: fluorescence in situ hybridization; MP: mutation profiling; NPV: negative predictive value; NR: not reported; PPV: positive predictive value.

Table 9. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Khosravi et al (2018) ⁴⁷ .					
Kushnir et al (2018) ⁴⁸ .	4. Participants had "biliary strictures," which may include conditions other than solid pancreatic lesions			3. Positive and negative predictive values not calculated	
Gonda et al (2017) ⁴⁹ .	4. Participants had "biliary strictures," which may include conditions other than solid pancreatic lesions			3. Positive and negative predictive values not calculated	

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Classification thresholds not defined; 2. Version used unclear; 3. Not intervention of interest.

^c Comparator key: 1. Classification thresholds not defined; 2. Not compared to credible reference standard; 3. Not compared to other tests in use for same purpose.

^d Outcomes key: 1. Study does not directly assess a key health outcome; 2. Evidence chain or decision model not explicated; 3. Key clinical validity outcomes not reported (sensitivity, specificity and predictive values); 4. Reclassification of diagnostic or risk categories not reported; 5. Adverse events of the test not described (excluding minor discomforts and inconvenience of venipuncture or noninvasive tests).

^e Follow-Up key: 1. Follow-up duration not sufficient with respect to natural history of disease (true positives, true negatives, false positives, false negatives cannot be determined).

Table 10. Study Design and Conduct Limitations

Study	Selection ^a	Blinding ^b	Delivery of Test ^c	Selective Reporting ^d	Data Completeness ^e	Statistical ^f
Khosravi et al (2018) ⁴⁷ .		1. No discussion whether cytologists blinded to other test results				
Kushnir et al (2018) ⁴⁸ .		1. No discussion whether cytologists blinded to other test results				1. Confidence intervals not reported
Gonda et al (2017) ⁴⁹ .		1. No discussion whether cytologists				

		blinded to other test results				
--	--	-------------------------------	--	--	--	--

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Selection key: 1. Selection not described; 2. Selection not random or consecutive (ie, convenience).

^b Blinding key: 1. Not blinded to results of reference or other comparator tests.

^c Test Delivery key: 1. Timing of delivery of index or reference test not described; 2. Timing of index and comparator tests not same; 3. Procedure for interpreting tests not described; 4. Expertise of evaluators not described.

^d Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^e Data Completeness key: 1. Inadequate description of indeterminate and missing samples; 2. High number of samples excluded; 3. High loss to follow-up or missing data.

^f Statistical key: 1. Confidence intervals and/or p values not reported; 2. Comparison to other tests not reported.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials.

No randomized controlled trials were identified that evaluated the clinical utility of PancreGEN for the classification of solid pancreaticobiliary lesions.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

An incremental benefit was seen in increased sensitivity when FISH plus MP were added to cytology alone. The sensitivity with cytology plus FISH plus MP averaged around 70%.

Whether the tradeoff between avoiding biopsies and the potential for missed cancers is worthwhile depends, in part, on patient and physician preferences. In the context of pancreaticobiliary cancers, overall survival depends on detection of these cancers at early, more treatable stages.

While there is indirect evidence that cytology plus FISH plus MP may predict more solid pancreaticobiliary lesions compared with cytology alone, the sensitivity is not sufficiently high enough to identify which patients can forego biopsy. Missing a solid pancreaticobiliary lesion diagnosis at a rate of 30%, is not inconsequential. A delay in diagnosis would delay potential treatment (surgery and/or chemotherapy).

Section Summary: Solid Pancreaticobiliary Lesions

The evidence for the clinical validity of using PancreGEN to evaluate solid pancreaticobiliary lesions consists of several retrospective studies. One study evaluated the performance characteristics of PancreGEN for classifying solid pancreatic lesions while the other two evaluated the classification of biliary strictures. Biliary strictures may be caused by solid pancreaticobiliary lesions but may have other causes. The authors of the studies did not specify what proportion of patients with biliary stricture had solid pancreaticobiliary lesions. The

studies reported sensitivities and specificities that were higher when PancreaGEN testing was added to cytology alone; however, not knowing the causes of biliary strictures does not permit conclusions specific to patients with solid pancreaticobiliary lesions. The manufacturer has indicated that the technology is meant as an adjunct to first-line testing, but no algorithm for combining PancreaGEN with consensus guidelines for decision making has been proposed. There are no prospective studies demonstrating that PancreaGEN can affect patient-relevant outcomes (e.g., survival, time to tumor recurrence, reduction in unnecessary surgeries). The evidence reviewed does not demonstrate that PathFinder^{TG} has incremental clinical value for the diagnosis of solid pancreatic lesions and associated cancer.

Whether the tradeoff between avoiding biopsies and the potential for missed cancers is worthwhile depends, in part, on patient and physician preferences. In the context of pancreaticobiliary cancers, overall survival depends on detection of these cancers at early, more treatable stages. While there is indirect evidence that cytology plus FISH plus MP may predict more solid pancreaticobiliary lesions compared with cytology alone, the sensitivity is not sufficiently high enough to identify which patients can forego biopsy. Missing a solid pancreaticobiliary lesion diagnosis at a rate of 30%, is not inconsequential. A delay in diagnosis would delay potential treatment (surgery and/or chemotherapy).

SUMMARY OF EVIDENCE

For individuals who have pancreatic cysts who do not have a definitive diagnosis after first-line evaluation and who receive standard diagnostic and management practices plus topographic genotyping (PancreaGEN molecular testing), the evidence includes retrospective studies of clinical validity and clinical utility. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, change in disease status, morbid events, and quality of life. The best evidence of incremental clinical validity comes from the National Pancreatic Cyst Registry report that compared PancreaGEN performance characteristics to current international consensus guidelines and provided preliminary but inconclusive evidence of a small incremental benefit for PancreaGEN. The analyses from the registry study included only a small proportion of enrolled patients, relatively short follow-up time for observing malignant transformation, and limited data on cases where the PancreaGEN results are discordant with international consensus guidelines. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have Barrett esophagus who receive standard prognostic techniques plus topographic genotyping (BarreGEN molecular testing), No studies were identified, the evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have solid pancreaticobiliary lesions who do not have a definitive diagnosis after first line evaluation and who receive standard diagnostic and management practices plus topographic genotyping (PancreaGEN molecular testing), the evidence includes 3 observational studies of clinical validity. Relevant outcomes are overall survival, disease-specific survival, test validity, change in disease status, morbid events, and quality of life. Two of the 3 studies had populations with biliary strictures and the other had a population of patients with solid pancreaticobiliary lesions. The studies reported higher sensitivities and specificities when PancreaGEN testing was added to cytology results compared with cytology alone. However, the inclusion of patients in the analysis who may not have solid pancreaticobiliary lesions (those with biliary strictures not caused by solid pancreaticobiliary lesions) limits the interpretation of the results. While preliminary results showed a potential

incremental benefit for PancreaGEN, further research focusing on patients with solid pancreaticobiliary lesions is warranted. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might impact this policy are listed in Table 11.

Table 11. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT03855800	Molecular Detection of Advanced Neoplasia in Pancreatic Cysts (IN-CYST)	800	Dec 2026
NCT02110498	Early Detection of Pancreatic Cystic Neoplasms	3000	Mar 2024
Unpublished			
NCT01202136	The Clinical, Radiologic, Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study (PCyst)	450	Sept 2019 (completed)
NCT02000999	The Diagnostic Yield of Malignancy Comparing Cytology, FISH and Molecular Analysis of Cell Free Cytology Brush Supernatant in Patients With Biliary Strictures Undergoing Endoscopic Retrograde Cholangiography (ERC): A Prospective Study	110	Jan 2019 (completed)

NCT: national clinical trial

SUPPLEMENTAL INFORMATION

PRACTICE GUIDELINES AND POSITION STATEMENTS

American Gastroenterological Association (AGA)

Two (now retired) American Gastroenterological Association (AGA) guidelines previously indicated that "molecular techniques to evaluate pancreatic cysts remain an emerging area of research, and the diagnostic utility of these tests is uncertain"⁴ and recommended "against the use of molecular biomarkers to confirm the histological diagnosis of dysplasia or as a method of risk stratification for patients with Barrett's esophagus."⁴³ As of May 2022, the AGA recommendation on the management of Barrett esophagus is in the process of being updated.

American College of Gastroenterology (ACG)

In 2022, the American College of Gastroenterology released guidelines on the diagnosis and management of Barrett esophagus.⁵⁰ The guidelines stated: "We could not make a recommendation on the use of predictive tools (p53 staining and TissueCypher) in addition to standard histopathology in patients undergoing endoscopic surveillance of BE." The BarreGEN test was not specifically addressed in the guidelines.

The College (2018) published guidelines on the diagnosis and management of pancreatic cysts.⁵³ The guidelines stated that the evidence for the use of molecular biomarkers for identifying high-grade dysplasia or pancreatic cancer is insufficient to recommend their routine use. However, molecular markers may help identify intraductal papillary mucinous neoplasms

and mucinous cystic neoplasms in cases with an unclear diagnosis and if results are likely to change the management (conditional recommendation; very low quality evidence).

National Comprehensive Cancer Network

Current National Comprehensive Cancer Network guidelines for pancreatic adenocarcinoma were updated in 2024 (v.1.2024) and recommend that clinicians consider tumor/somatic molecular profiling for patients with locally advanced/metastatic disease who are candidates for anti-cancer therapy to identify uncommon mutations. Consider specifically testing for potentially actionable somatic findings including, but not limited to: fusions (ALK, NRG1, NTRK, ROS1, FGFR2, and RET), mutations (BRAF, BRCA1/2, KRAS, and PALB2), amplifications (HER2), microsatellite instability (MSI), mismatch repair deficiency (dMMR), or tumor mutational burden (TMB) via an FDA-approved and/or validated next-generation sequencing (NGS)-based assay. RNA sequencing assays are preferred for detecting RNA fusions because gene fusions are better detected by RNA-based NGS. ... (Also for PANC-5, PANC-6A, PANC-9, PANC-10, PANC-11)

NCCN guidelines for central nervous system cancers (v.1.2023)⁵⁵ recommends molecular profiling to identify clinically relevant subtypes to encourage opportunities for clinical trial involvement. There are no identified targeted agents with demonstrated efficacy in glioblastoma. However, the panel encourages molecular testing of tumor because if a driver mutation is detected, it may be reasonable to treat with a targeted therapy on a compassionate use basis and/or the patient may have more treatment options in the context of a clinical trial. Molecular testing also has a valuable role in improving diagnostic accuracy and prognostic stratification that may inform treatment selection

NCCN guidelines for esophageal and esophagogastric junction cancers (v.3.2023),⁵⁶ State for patients with inoperable locally advanced, recurrent, or metastatic adenocarcinoma of the esophagus or EGJ for whom trastuzumab therapy is being considered, assessment for tumor HER2 overexpression using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) methods is recommended.¹¹ NGS offers the opportunity to assess numerous mutations simultaneously, along with other molecular events such as amplification, deletions, tumor mutation burden, and MSI status. NGS can be considered instead of sequential testing for single biomarkers when limited diagnostic tissue is available or when the patient is unable to undergo a traditional biopsy. The use of IHC/ISH should be considered first, followed by NGS testing as appropriate. Repeat biomarker testing may be considered at clinical or radiologic progression for patients with advanced/metastatic esophageal/EGJ adenocarcinoma.

Network guidelines on hepatobiliary cancers (v.2.2023) state that molecular testing may be considered in the following situations⁵⁹:

- Hepatocellular carcinomas are associated with a range of molecular alterations, including activation of oncogenic signaling pathways, such as Wnt-TGF β , PI3K-AKT-mTOR, RAS-MAPK, MET, IGF, and Wnt- β -catenin; TP53 and TERT promoter mutations are also common.¹ To date, however, there are no treatments with differential benefit for specific molecularly defined subgroups of HCC.
- Molecular profiling in HCC: There is no established indication for routine molecular profiling in HCC. Tumor molecular testing may be warranted in patients with atypical histology, cHCC-CCA histology, or unusual clinical presentations.

- Germline testing in hepatobiliary cancers: Evidence remains insufficient for definitive recommendations regarding specific criteria to guide genetic risk assessment in hepatobiliary cancers or for universal germline testing in these tumors. Immunotherapy Biomarkers (MSI-H/dMMR/TMB-H, PD-L1)

Recommendation:

- There is no established role for microsatellite instability (MSI), mismatch repair (MMR), tumor mutational burden (TMB), or PD-L1 testing in HCC at this time. Immune checkpoint inhibition has shown clinical benefit leading to regulatory approvals in patients with HCC without selection for MSI, MMR, TMB, or PD-L1 status.²⁻

Government Regulations

National:

There is no national coverage determination.

Local:

There is no local coverage determination for Michigan (Medicare Jurisdiction 8).

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)

Related Policies

N/A

References

1. Scholten L, van Huijgevoort NCM, van Hooft JE, et al. Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines. *Visc Med.* Jul 2018; 34(3): 173-177. PMID 30182024
2. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology.* May-Jun 2012; 12(3): 183-97. PMID 22687371
3. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatology.* 2006; 6(1-2): 17-32. PMID 16327281
4. Vege SS, Ziring B, Jain R, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology.* Apr 2015; 148(4): 819-22; quiz 823-3. PMID 25805375
5. Abrams JA, Fields S, Lightdale CJ, et al. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. *Clin Gastroenterol Hepatol.* Jan 2008; 6(1): 30-4. PMID 18063419
6. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia,

- Indefinite for, or Low-Grade Dysplasia. *Am J Gastroenterol*. May 2015; 110(5): 662-82; quiz 683. PMID 25869390
7. Shaheen NJ, Falk GW, Iyer PG, et al. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am J Gastroenterol*. Jan 2016; 111(1): 30-50; quiz 51. PMID 26526079
 8. Trikalinos T, Terasawa T, Raman G, et al. Technology Assessment: A systematic review of loss-of-heterozygosity based topographic genotyping with PathfinderTG. Rockville, MD: Agency for Healthcare Research and Quality;2010.
 9. U.S. Patent #7,014,999. Finkelstein et al. March 21, 2006. Topographic genotyping. <https://patft.uspto.gov/netahtml/PTO/index.html>. Accessed May 27, 2021.
 10. Interpace Diagnostics. Advancing patient care through molecular diagnostic testing. 2022; <https://www.interpace.com/diagnostic-products>. Accessed May 25, 2022.
 11. de Oliveira PB, Puchnick A, Szejnfeld J, et al. Prevalence of incidental pancreatic cysts on 3 tesla magnetic resonance. *PLoS One*. 2015; 10(3): e0121317. PMID 25798910
 12. Laffan TA, Horton KM, Klein AP, et al. Prevalence of unsuspected pancreatic cysts on MDCT. *AJR Am J Roentgenol*. Sep 2008; 191(3): 802-7. PMID 18716113
 13. de Jong K, Nio CY, Hermans JJ, et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. *Clin Gastroenterol Hepatol*. Sep 2010; 8(9): 806-11. PMID 20621679
 14. Gardner TB, Glass LM, Smith KD, et al. Pancreatic cyst prevalence and the risk of mucin-producing adenocarcinoma in US adults. *Am J Gastroenterol*. Oct 2013; 108(10): 1546-50. PMID 24091499
 15. Khalid A, Brugge W. ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. *Am J Gastroenterol*. Oct 2007; 102(10): 2339-49. PMID 17764489
 16. Oh HC, Kim MH, Hwang CY, et al. Cystic lesions of the pancreas: challenging issues in clinical practice. *Am J Gastroenterol*. Jan 2008; 103(1): 229-39; quiz 228, 240. PMID 18076739
 17. Scheiman JM, Hwang JH, Moayyedi P. American gastroenterological association technical review on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology*. Apr 2015; 148(4): 824-48.e22. PMID 25805376
 18. Interpace Diagnostics. Clinical utility. 2022; <https://pancragen.com/clinical-utility/>. Accessed May 25, 2022.
 19. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. *Endoscopy*. Feb 2015; 47(2): 136-42. PMID 25314329
 20. Khalid A, McGrath KM, Zahid M, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. *Clin Gastroenterol Hepatol*. Oct 2005; 3(10): 967-73. PMID 16234041
 21. Khalid A, Nodit L, Zahid M, et al. Endoscopic ultrasound fine needle aspirate DNA analysis to differentiate malignant and benign pancreatic masses. *Am J Gastroenterol*. Nov 2006; 101(11): 2493-500. PMID 17029619
 22. Khalid A, Pal R, Sasatomi E, et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. *Gut*. Dec 2004; 53(12): 1860-5. PMID 15542529
 23. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. *Gastrointest Endosc*. May 2009; 69(6): 1095-102. PMID 19152896

24. Siddiqui AA, Kowalski TE, Kedika R, et al. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study. *Gastrointest Endosc.* Apr 2013; 77(4): 669-70. PMID 23498145
25. Schoedel KE, Finkelstein SD, Ohori NP. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. *Diagn Cytopathol.* Sep 2006; 34(9): 605-8. PMID 16900481
26. Sawhney MS, Devarajan S, O'Farrel P, et al. Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid. *Gastrointest Endosc.* May 2009; 69(6): 1106-10. PMID 19249035
27. Sreenarasimhaiah J, Lara LF, Jazrawi SF, et al. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts. *JOP.* Mar 09 2009; 10(2): 163-8. PMID 19287110
28. Mertz H. K-ras mutations correlate with atypical cytology and elevated CEA levels in pancreatic cystic neoplasms. *Dig Dis Sci.* Jul 2011; 56(7): 2197-201. PMID 21264513
29. Talar-Wojnarowska R, Pazurek M, Durko L, et al. A comparative analysis of K-ras mutation and carcinoembryonic antigen in pancreatic cyst fluid. *Pancreatology.* Sep-Oct 2012; 12(5): 417-20. PMID 23127529
30. Chai SM, Herba K, Kumarasinghe MP, et al. Optimizing the multimodal approach to pancreatic cyst fluid diagnosis: developing a volume-based triage protocol. *Cancer Cytopathol.* Feb 2013; 121(2): 86-100. PMID 22961878
31. Nikiforova MN, Khalid A, Fasanella KE, et al. Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. *Mod Pathol.* Nov 2013; 26(11): 1478-87. PMID 23743931
32. Lapkus O, Gologan O, Liu Y, et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. *Mod Pathol.* Jul 2006; 19(7): 907-13. PMID 16648872
33. Tamura K, Ohtsuka T, Date K, et al. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers. *Pancreas.* Jul 2016; 45(6): 826-35. PMID 26646266
34. Panarelli NC, Sela R, Schreiner AM, et al. Commercial molecular panels are of limited utility in the classification of pancreatic cystic lesions. *Am J Surg Pathol.* Oct 2012; 36(10): 1434-43. PMID 22982886
35. Toll AD, Kowalski T, Loren D, et al. The added value of molecular testing in small pancreatic cysts. *JOP.* Nov 09 2010; 11(6): 582-6. PMID 21068490
36. Kung JS, Lopez OA, McCoy EE, et al. Fluid genetic analyses predict the biological behavior of pancreatic cysts: three-year experience. *JOP.* Sep 28 2014; 15(5): 427-32. PMID 25262708
37. Shen J, Brugge WR, Dimaio CJ, et al. Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. *Cancer.* Jun 25 2009; 117(3): 217-27. PMID 19415731
38. Deftereos G, Finkelstein SD, Jackson SA, et al. The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions. *Mod Pathol.* Apr 2014; 27(4): 594-601. PMID 24051700
39. Winner M, Sethi A, Ponerros JM, et al. The role of molecular analysis in the diagnosis and surveillance of pancreatic cystic neoplasms. *JOP.* Mar 20 2015; 16(2): 143-9. PMID 25791547

40. Malhotra N, Jackson SA, Freed LL, et al. The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. *BMC Gastroenterol*. Aug 01 2014; 14: 135. PMID 25084836
41. Loren D, Kowalski T, Siddiqui A, et al. Influence of integrated molecular pathology test results on real-world management decisions for patients with pancreatic cysts: analysis of data from a national registry cohort. *Diagn Pathol*. Jan 20 2016; 11: 5. PMID 26790950
42. Kowalski T, Siddiqui A, Loren D, et al. Management of Patients With Pancreatic Cysts: Analysis of Possible False-Negative Cases of Malignancy. *J Clin Gastroenterol*. Sep 2016; 50(8): 649-57. PMID 27332745
43. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. *Gastroenterology*. Mar 2011; 140(3): 1084-91. PMID 21376940
44. Yantiss RK. Diagnostic challenges in the pathologic evaluation of Barrett esophagus. *Arch Pathol Lab Med*. Nov 2010; 134(11): 1589-600. PMID 21043812
45. Khara HS, Jackson SA, Nair S, et al. Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus. *J Gastrointest Cancer*. Jun 2014; 45(2): 137-45. PMID 24402860
46. Eluri S, Brugge WR, Daglilar ES, et al. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus. *Am J Gastroenterol*. Jun 2015; 110(6): 828-34. PMID 26010308
47. Khosravi F, Sachdev M, Alshati A, et al. Mutation profiling impacts clinical decision making and outcomes of patients with solid pancreatic lesions indeterminate by cytology. *JOP (Online)*. 2018;19(1):6-11.
48. Kushnir VM, Mullady DK, Das K, et al. The Diagnostic Yield of Malignancy Comparing Cytology, FISH, and Molecular Analysis of Cell Free Cytology Brush Supernatant in Patients With Biliary Strictures Undergoing Endoscopic Retrograde Cholangiography (ERC): A Prospective Study. *J Clin Gastroenterol*. Oct 2019; 53(9): 686-692. PMID 30106834
49. Gonda TA, Viterbo D, Gausman V, et al. Mutation Profile and Fluorescence In Situ Hybridization Analyses Increase Detection of Malignancies in Biliary Strictures. *Clin Gastroenterol Hepatol*. Jun 2017; 15(6): 913-919.e1. PMID 28017843
50. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol*. Apr 01 2022; 117(4): 559-587. PMID 35354777
51. Elta GH, Enestvedt BK, Sauer BG, et al. ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts. *Am J Gastroenterol*. Apr 2018; 113(4): 464-479. PMID 29485131
52. Centers for Medicare and Medicaid Services. Local Coverage Determination: Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG. Accessed May 25, 2022.
53. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed January 2024.
54. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers. Version 1.2023.

- https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed January 2024.
55. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed January 2024.
56. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 2.2023. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed January 2024.
57. Blue Cross Blue Shield Association. Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreatic Lesions. MPRM 2.04.52. Last reviewed August 2023.

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through January 2024, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
11/1/08	10/9/08	11/1/08	Joint policy established
3/1/10	12/8/09	12/8/09	Routine maintenance
11/1/11	8/16/11	8/16/11	Routine update of experimental and investigational service. Added additional rationale; refreshed references. Policy statement unchanged.
11/1/13	8/22/13	8/27/13	Routine maintenance
5/1/15	2/17/15	2/27/15	Routine maintenance Updated references and rationale; added information regarding Barrett's esophagus Added Medicare LCD from Novitas
5/1/16	2/16/16	2/16/16	Routine maintenance with reference update.
5/1/17	2/21/17	2/21/17	<ul style="list-style-type: none"> • Updated policy title throughout policy for consistency • Updated background section • Rationale section reformatted, study results summarized, individual studies displayed in chart format • Policy focus on Pancreatic Cysts and Barrett Esophagus, Glioma section removed since PathFinder[™] Glioma is not commercially available. • CMS section updated with coverage criteria
5/1/18	2/20/18	2/20/18	Updated rationale, added references # 33 & 46. Policy title changed. Added PancaGEN and BarreGEN to policy statement as exclusions.

5/1/19	2/19/19		Rationale updated; references 50-52 and 54 added. Policy revised with an additional indication – “Individuals with solid pancreaticobiliary lesions who do not have a definitive diagnosis after first line evaluation.” Policy statements unchanged. The title of this policy was changed to “Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreaticobiliary Lesions.”
5/1/19	2/18/20		Routine policy maintenance. No added references, no change in policy status.
5/1/21	2/16/21		Routine policy maintenance. No change in policy status.
5/1/22	2/15/22		Routine policy maintenance. No change in policy status.
5/1/23	2/21/23		Rationale updated, references added, no change in policy status. Added code 0313U as E/I. (ds)
5/1/24	2/20/24		Routine policy maintenance, no change in status. Vendor managed: N/A (ds)

Next Review Date: 1st Qtr. 2025

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY GENETIC TESTING- MOLECULAR TESTING FOR THE DIAGNOSIS AND
MANAGEMENT OF PANCREATIC CYSTS, BARRETT ESOPHAGUS, AND SOLID
PANCREATICOBILIARY LESIONS (E.G., PATHFINDERTG®, PANCRAGEN, BARREGEN)

I. Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered
BCNA (Medicare Advantage)	See government section
BCN65 (Medicare Complementary)	Coinsurance covered if primary Medicare covers the service.

II. Administrative Guidelines:

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.